NAD+ 1G & TIRZEPATIDE'S SUCCESSOR : A UNITED KINGDOM UPDATE

The emerging interest in NAD+ supplementation, particularly at a substantial dosage of 1g , continues to rise within the United Kingdom pharmaceutical community. Concurrently, attention is focused on Retatrutide, a groundbreaking GLP-1 medication being viewed by many as a potential successor to T